Xvivo Perfusion AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XVIPY research report →
Companywww.xvivoperfusion.com
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP.
- CEO
- Christoffer Rosenblad
- IPO
- 2022
- Employees
- 170
- HQ
- Gothenburg, SE
Price Chart
Valuation
- Market Cap
- $206.01M
- P/E
- 122.48
- P/S
- 10.84
- P/B
- 4.17
- EV/EBITDA
- 65.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.21%
- Op Margin
- 11.79%
- Net Margin
- 8.85%
- ROE
- 3.49%
- ROIC
- 3.28%
Growth & Income
- Revenue
- $763.43M · -7.17%
- Net Income
- $23.65M · -86.26%
- EPS
- $0.19 · -86.29%
- Op Income
- $87.44M
- FCF YoY
- -82.98%
Performance & Tape
- 52W High
- $8.74
- 52W Low
- $4.25
- 50D MA
- $6.45
- 200D MA
- $6.45
- Beta
- 1.42
- Avg Volume
- 200
Get TickerSpark's AI analysis on XVIPY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our XVIPY Coverage
We haven't published any research on XVIPY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XVIPY Report →